

Original Article

To determine the glycated haemoglobin, total protein and albumin levels in type 2 diabetes mellitus patients

Vikram Kumar

Assistant Professor, Department of Pathology, Hind Institute of Medical Sciences College, Lucknow, Uttar Pradesh, India

ABSTRACT:

Aim: To determine the glycated haemoglobin, total protein and albumin levels in type 2 diabetes mellitus patients. **Methods:** This case control study was done the Department of Pathology. A total of 90 subjects comprising of 45 diabetic subjects and 45 controls aged between 35 and 70 years were recruited for the study. 5mls of blood sample was collected from each patient and 1ml was dispensed into EDTA for the estimation of glycated haemoglobin, and 4ml was dispensed into plain containers for estimation of serum albumin and total protein levels. Determination of glycated haemoglobin level, estimation of serum albumin level and estimation of total protein done by standard methods. **Results:** The mean level of HbA1c was significantly higher in the diabetic subjects when compared with control group (11.56 ± 1.79 Vs 7.21 ± 0.98 ; $p=0.001$). There was no significant differences observed between the age, the serum levels of Albumin and Total protein in the test and control subjects ($p>0.05$). **Conclusion:** we concluded that the present study showed significantly higher mean levels of HbA1c in the diabetic patients compared with the control subjects.

Keywords: Glycated haemoglobin, Protein, albumin, Type 2 diabetes mellitus

Received: 18 June, 2018

Accepted: 23 July, 2018

Corresponding author: Vikram Kumar, Assistant Professor, Department of Pathology, Hind Institute of Medical Sciences College, Lucknow, Uttar Pradesh, India

This article may be cited as: Kumar V. To determine the glycated haemoglobin, total protein and albumin levels in type 2 diabetes mellitus patients. J Adv Med Dent Sci Res 2018;6(8):193-196.

INTRODUCTION

Diabetes mellitus (DM) refers to a group of metabolic disorders characterized by elevated blood glucose concentrations. The majority (90–95%) of DM patients have type 2 DM (T2DM), which is characterized by peripheral insulin resistance and an inability of pancreatic beta cells to compensate for that by increasing insulin secretion.¹ Current diagnostic criteria of the World Health Organization (WHO) for the diagnosis of T2DM include glycosylated hemoglobin (HbA1c) levels ($\geq 6.5\%$ (48 mmol/mol)), elevated fasting plasma glucose (FPG) concentrations ($\text{FPG} \geq 7.0 \text{ mmol/L}$) and/or plasma glucose concentrations 2 h after a 75 g oral glucose load ($\geq 11.1 \text{ mmol/L}$) in the context of a standardized oral glucose tolerance test (OGTT).² The results of the Diabetes Control and Complications Trial (DCCT) and the UK Prospective Diabetes Study (UKPDS) demonstrated that importance of tight glucose control for the prevention of complications of diabetes and of HbA1c as an indicator of mean glycaemia.³ Early diagnosis and monitoring are therefore critical to

delay the onset of complications. Although glucose measurement, either fasting or 2 h post prandial, is considered the gold standard for diagnosis it is subject to several limitations. This led to a search for alternatives such as haemoglobin A1c (HbA1c) which can be used both for monitoring and diagnosis.⁴ Since the 1990s, World Health Organization (WHO) and the diabetes association's or societies in many countries have recommended HbA1c as the preferred diagnostic index for monitoring diabetes but more recently has also been advocated as a diagnostic tool for T2DM⁵, while HbA1c is also generally recognized as the "gold standard" for blood glucose testing. However, HbA1c has some limitations. Several studies have shown that HbA1c cannot be used to accurately assess blood glucose levels under certain circumstances, such as changes in red blood cell life and imbalance in the proportion of young and mature erythrocytes^{6,7}, Hb metabolic disorders and the use of erythropoietin.^{8,9} Glycated serum protein (GSP) is a product of non-enzymatic reaction between blood glucose and plasma protein (approximately 70% of which is albumin).

The determination of glycosylated serum protein (GSP) is also called fructosamine determination. Glycosylated serum protein (GSP) measurement reflects the total glycosylated plasma protein in plasma, its value is susceptible to the influence of protein concentration, bilirubin, chyle and low molecular weight substances in blood, especially in patients with hypoproteinemia and abnormal albumin transformation. At the same time, non-specific reducing substances in serum can also react with glycation sites. The specificity of glycosylated serum protein (GSP) assay is poor because of the different reaction rates. GA is an emerging indicator for blood glucose monitoring; several studies have suggested that GA is more suitable in patients with certain diseases, such as hemolytic anemia, hepatic cirrhosis with hyperglycemia, than HbA1c.^{10,11} GA is the product of glucose and serum albumin in non-enzymatic reactions, representing the average level of blood glucose in recent 2–3 weeks. GA relative to HbA1c can better reflect the changes or fluctuations in blood glucose level. In addition, several investigators have suggested that, compared with HbA1c, GA is more suitable as a diagnostic parameter for recessive diabetes and stress hyperglycemia¹² and as a monitoring glycemic control in patients with anemia.¹³ Although there are many advantages of GA over HbA1c, it also has some limitations that it could be affected by changes in the structure and half-life of albumin.¹⁴ In patients with aplastic anemia, the red blood cell life and hemoglobin metabolism are affected by their abnormal proliferation of bone marrow. Therefore, it is particularly important to develop and screening of diabetes and monitoring of glycemic control status for patients with aplastic anemia and those with diabetes. At present, there is no report on comparative studies of the application value of blood glucose monitoring indexes in patients with aplastic anemia in China.

MATERIAL AND METHODS

This case control study was done the Department of Pathology, after taking the approval of the protocol review committee and institutional ethics committee. After taking informed consent detailed history was taken from the patient or relatives.

A total of 90 subjects comprising of 45 diabetic subjects and 45 controls aged between 35 and 70 years were recruited for the study. The patients and controls were aged and sex matched. Subsequently, structured questionnaire were used to obtain patients' biodata and thereafter, 5mls of blood sample was collected from each patients and 1ml was dispensed into EDTA for the estimation of glycated haemoglobin, and 4ml was dispensed into plain containers for estimation of serum albumin and total protein levels. Known diabetic subjects aged between 35 and 75 years were included in this study. Younger than 35 or older than 70 years and non-diabetic subjects were excluded from the study.

Determination of glycated haemoglobin level Glycated Haemoglobin level was determined using immunoturbidimetric method as described by Wolf et al.¹⁵ Estimation of serum albumin level Serum albumin level was estimated Bromo Cresol green Method as described by Doumas et al.¹⁶ Estimation of total protein Estimation of serum total protein level was done using Biuret Method according to Weichselbaum et al.¹⁷ The data were presented as mean±SD and the mean values of the control and test group were compared by Students t-test and pearson correlation using Statistical package for social sciences (SPSS) (Version 25.0) software. Statistical significance was tested at P<0.05.

RESULTS

The mean level of HbA1c was significantly higher in the diabetic subjects when compared with control group (11.56±1.79Vs 7.21±0.98; p=0.001). There was no significant differences observed between the age, the serum levels of Albumin and Total protein in the test and control subjects (p>0.05).

Table 1 Table 1: Levels of HbA1c, total protein and albumin in diabetic and control patients

Parameters	Control	Diabeticsubject	t- test	p- value
Age(years)	56.96±8.85	57.88±8.68	-	0.77
HbA1c(%)	7.21±0.98	11.56±1.79	1.89	0.001
Protein(g/L)	75.25±3.03	71.96±3.69	1.55	0.17
Albumin(g/L)	41.36±2.88	41.69±3.45	0.29	0.59

Table 2 shows that there is no significant correlation between age, HbA1c, total protein and albumin in diabetic patients.

Table 2: Correlation of HbA1c with age, total protein and albumin in diabetic patients

Parameters	R	p-value
HbA1c Vs age	0.083	0.57
HbA1c Vs Total protein	0.094	0.55
HbA1c Vs Albumin	-0.175	0.35
Age Vs Total protein	-0.067	0.85
Age Vs Albumin	0.086	0.64
Total protein Vs	-0.006	0.87

DISCUSSION

In this study, the mean level of HbA1c was significantly higher in the diabetic subjects than in control. This is in consonance with the report of some previous similar studies. This increase can be attributed to hyperglycaemia and disturbances of carbohydrate, fat and protein metabolism that results from abnormalities in insulin secretion, insulin action or even both.^{17,18} This finding implies that there is a poor glycemic control in the diabetic subjects under study. Furthermore, our finding shows a higher mean value of HbA1c (11.56±1.79) than the recommended cut point (<0.001). This is in line with the report of previous studies.¹⁷ This may be as a result of Insulin resistance which is a principal cause of type 2 diabetes (Kahn, 1994)¹⁹ and previously, serum albumin has been associated with insulin resistance.^{20,21} In diabetic patients, plasma albumin concentration has been reported to be inversely related with HbA1c levels, revealing a large proportion of poorly controlled diabetes in patients with lower plasma albumin concentrations.^{22,23} This inverse relationship may also be explained by the fact that poorly controlled type 2 diabetes has been associated with a further decrease in insulin production and secretion by the pancreatic β -cell.²³ Furthermore, our finding shows no significant difference between the serum levels of total protein in the diabetic patients and control subjects ($p>0.05$). There is no significant correlation between age, HbA1c, total protein and albumin in diabetic subjects. This finding is not in agreement with the finding of Hemangi et al.²² in which plasma albumin levels were negatively correlated with HbA1c and low albumin levels was associated with increased plasma protein glycation and that albumin competes for glycation with other plasma proteins in diabetes.

CONCLUSION

We concluded that the present study showed significantly higher mean levels of HbA1c in the diabetic patients compared with the control subjects.

REFERENCE

1. American Diabetes Association (ADA). Diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2013;36:67–74.
2. World Health Organization (WHO) and International Diabetes Federation (IDF). Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. Geneva: World Health Organization; 2006
3. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *NEJM*. 1993;329:977–86.
4. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. *Diabetes Care*. 2009;32:1327–34
5. John, W.G. and Diabetes UKDoHACo (2012) Use of HbA1c in the diagnosis of diabetes mellitus in the UK.

The implementation of World Health Organization guidance 2011. *Diabet Med*. 29, 1350–1357

6. Nakao, T., Matsumoto, H., Okada, T. et al. (1998) Influence of erythropoietin treatment on hemoglobin A1c levels in patient with chronic renal failure on hemodialysis. *Intern. Med*. 38, 826–830.
7. Fitzgibbons, J.F., Koler, R.D. and Jones, R.T. (1976) Red cell age-related changes of hemoglobins A1a+b and A1c in normal and diabetic subjects. *cJ Clin Invest*. 58, 820–824.
8. Kim, S., Min, W.K.I. and Chun, S. (2011) Glycated albumin may be a possible alternative to hemoglobin A1c in diabetic patients with anemia. *Clin. Chem. Lab. Med*. 49, 1743–1747.
9. Inaba, M., Okuno, S., Kumeda, Y. et al. (2007) Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. *J. Am. Soc. Nephrol*. 18, 896–903
10. Koga, M., Hashimoto, K., Murai, J. et al. (2011) Usefulness of glycated albumin as an indicator of glycemic control status in patients with hemolytic anemia. *Clin. Chim. Acta* 412, 253–257
11. Furusyo, N. and Hayashi, J. (2013) Glycated albumin and diabetes mellitus. *Biochim. Biophys. Acta* 12, 5509–5514
12. Pan, J., Zou, J., Bao, Y. et al. (2012) Use of glycated albumin to distinguish occult diabetes mellitus from stress-induced hyperglycemia in Chinese orthopedic trauma patients. *J. Trauma Acute Care Surg*. 5, 1369–1374,
13. Koga, M., Saito, H., Mukai, M., Matsumoto, S. and Kasayama, S. (2010) Influence of iron metabolism indices on glycated haemoglobin but not glycated albumin levels in premenopausal women. *Acta Diabetol*. 47,
14. Koga, M. and Kasayama, S. (2010) Clinical impact of glycated albumin as another glycemic control marker. *Endocr. J*. 57, 751–762.
15. Wolf HU, Lang W, Zander R. Alkaline haematin D-575, a new tool for the determination of haemoglobin as an alternative to the cyanhaemoglobin method. II. Standardization of the method using pure chlorohaemin. *Clinica Chimica Acta*. 1984;136:95–104.
16. Doumas BT, Watson WA, Biggs HG. Albumin standards and the measurement of serum albumin with bromocresol green. *Clinica Chimica Acta*. 1971;31:87–96.
17. Weichselbaum TE. An accurate and rapid method for the determination of proteins in small amounts of blood serum and plasma. *Am J Clin Pathol*. 1946;10:40–49
18. Kahn CR, Lecture B. Insulin action, diabetogenes, and the cause of type II diabetes. *Diabetes*. 1994;43:1066–1084.
19. Hostmark AT, Tomten SE, Berg JE. Serum albumin and blood pressure: a population-based, cross-sectional study. *J Hypertens*. 2005;23:725–730.
20. Ishizaka N, Ishizaka Y, Nagai R, Toda E, Hashimoto H, Yamakado M. Association between serum albumin, carotid atherosclerosis, and metabolic syndrome in Japanese individuals. *Atheroscler*. 2007;193:373–379.
21. Hemangi SB, Arvind MK, Sachin SK, Sandeep BG, Ashok DC, et al. Low Plasma Albumin Levels Are Associated with Increased Plasma Protein

- Glycation and HbA1c in Diabetes. *J Proteome Res.* 2012;11(2):1391–1396.
22. Rodriguez-Segade S, Rodriguez J, Mayan D, Camina F. Plasma albumin concentration is a predictor of HbA1c among type 2 diabetic patients, independently of fasting plasma glucose and fructosamine. *Diabetes Care.* 2005;28:437–439.
23. Kahn SE. The relative contributions of insulin resistance and beta- cell dysfunction to the pathophysiology of type 2 diabetes. *Diabetol.* 2003;46:3–19.